Patients with HPV-positive oropharynx cancer should receive chemoradiation
(European Society for Medical Oncology) Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking research reported at the ESMO 2018 Congress in Munich. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news
No Change in Standard of Care for HPV+ Oropharyngeal Cancer No Change in Standard of Care for HPV+ Oropharyngeal Cancer
Interim results of a large phase III trial showed that patients treated with a cetuximab regimen has worse survival than those treated with cisplatin plus radiation therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cetuximab Failure in HPV+ Head and Neck Cancer
(MedPage Today) -- Inferior survival when paired with radiation therapy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 16, 2018 Category: American Health Source Type: news
Chemicals in green vegetables show to prevent bowel cancer
Diets high in indole-3-carbinol protect stomach cells from chaotic division Related items fromOnMedica FOB associated with rise in all-cause mortality Colorectal cancer risk link to ‘inflammatory’ foods Taking aspirin with a PPI reduces risk of oesophageal cancer Cetuximab with chemo shrinks more secondaries Overweight teens more likely to have severe liver disease later (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 15, 2018 Category: UK Health Source Type: news
Study: Cetuximab, radiation inferior to standard HPV throat cancer treatment
Treating HPV-positive throat cancer with cetuximab and radiation had worse overall and progression-free survival compared with radiation and cisplatin. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 14, 2018 Category: Consumer Health News Source Type: news
Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 14, 2018 Category: American Health Source Type: news
Cetuximab+RT found to be inferior to standard treatment in HPV+ oropharyngeal cancer
(NIH/National Cancer Institute) An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall and progression-free survival compared to the current standard treatment with radiation and cisplatin. The trial was designed to see if cetuximab with radiation would be less toxic than cisplatin with radiation without compromising survival for patients with the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 14, 2018 Category: Cancer & Oncology Source Type: news
Clinical trial suggests new direction for heavy-smoking head and neck cancer patients
(University of Colorado Anschutz Medical Campus) Phase I results of olaparib with cetuximab and radiation led to 72 percent 2-year survival in 16 patients on trial, compared with an expected 2-year survival rate of about 55 percent for standard-of-care treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2018 Category: International Medicine & Public Health Source Type: news
Can New Algorithm Shed Light on Treatment Resistance in Head and Neck Cancer?
The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team. (Source: CancerNetwork)
Source: CancerNetwork - July 30, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Pazopanib/Cetuximab Combo Promising in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
A Washington University School of Medicine team ’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
A Better Regimen for Head and Neck Cancer?
(MedPage Today) -- Study backs combo of chemotherapy, cetuximab, and radiotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news
Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Cetuximab and panitumumab cost effective for mCRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news
A specific new ELISA method for analyzing cetuximab
This study describes the development and full validation of a new enzyme-linked immunosorbent assay (ELISA) with high sensitivity and selectivity for bioanalysis of CET. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2018 Category: Cancer & Oncology Source Type: news
Therapy Order Affects Survival in Metastatic CRC
(MedPage Today) -- Big gain with regorafenib before cetuximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 21, 2018 Category: Primary Care Source Type: news
